Imprinting of IgA responses in previously infected individuals receiving bivalent mRNA vaccines (WT and BA.4/BA.5 or WT and BA.1)

•Immune escape of SARS-CoV-2 variants spurred the development of bivalent vaccines.•We compared antibody response following monovalent or bivalent mRNA vaccination.•While IgG responses are similar, IgA responses are lower post bivalent booster.•IgA are particularly lower in bivalent-booster-vaccinee...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of infectious diseases Vol. 146; p. 107147
Main Authors Goh, Yun Shan, Fong, Siew‐Wai, Hor, Pei Xiang, Loh, Chiew Yee, Tay, Matthew Zirui, Wang, Bei, Salleh, Siti Nazihah Mohd, Ngoh, Eve Zi Xian, Lee, Raphael Tze Chuen, Poh, Xuan Ying, Lee, I. Russel, Rao, Suma, Chia, Po Ying, Maurer-Stroh, Sebastian, Wang, Cheng-I, Leo, Yee‐Sin, Lye, David C., Young, Barnaby Edward, Ng, Lisa F.P., Renia, Laurent
Format Journal Article
LanguageEnglish
Published Canada Elsevier Ltd 01.09.2024
Elsevier
Subjects
Online AccessGet full text
ISSN1201-9712
1878-3511
1878-3511
DOI10.1016/j.ijid.2024.107147

Cover

Abstract •Immune escape of SARS-CoV-2 variants spurred the development of bivalent vaccines.•We compared antibody response following monovalent or bivalent mRNA vaccination.•While IgG responses are similar, IgA responses are lower post bivalent booster.•IgA are particularly lower in bivalent-booster-vaccinees with prior infection.•IgA are skewed towards WT in bivalent-booster-vaccinees with prior infection. The emergence of new SARS-CoV-2 variants has led to the development of Omicron-targeting bivalent mRNA vaccines. It is crucial to understand how bivalent vaccines may improve antibody responses against new variants. A total of 107 participants, who had three COVID-19 WT mRNA vaccine doses, were recruited, and given either a monovalent (WT) or a bivalent mRNA vaccination (Pfizer/BioNTech Bivalent (WT and BA.4/BA.5) or Moderna Bivalent (WT and BA.1). Blood samples were taken before booster and at 28 days post-booster. We found significantly lower fold change in serum binding IgA responses against BA.1, BA.5 and EG.5.1 spike in the bivalent booster group, compared with the monovalent (WT) booster group, following vaccination. However, this was only observed in individuals with prior infection. The relative fold change in serum binding IgA response was more skewed towards WT over variant (BA.1, BA.5 or EG.5.1) spike in previously infected bivalent-booster-vaccinees, as compared with previously infected monovalent-(WT)-booster-vaccinees. The findings suggest imprinting of antibody responses that is shaped by the first vaccination (WT spike). Previous infection also affects the boosting effect of follow-up vaccination. Studies are needed to understand how to induce a robust and long-lasting IgA immunity for protection against COVID-19 infection.
AbstractList Objectives: The emergence of new SARS-CoV-2 variants has led to the development of Omicron-targeting bivalent mRNA vaccines. It is crucial to understand how bivalent vaccines may improve antibody responses against new variants. Methods: A total of 107 participants, who had three COVID-19 WT mRNA vaccine doses, were recruited, and given either a monovalent (WT) or a bivalent mRNA vaccination (Pfizer/BioNTech Bivalent (WT and BA.4/BA.5) or Moderna Bivalent (WT and BA.1). Blood samples were taken before booster and at 28 days post-booster. Results: We found significantly lower fold change in serum binding IgA responses against BA.1, BA.5 and EG.5.1 spike in the bivalent booster group, compared with the monovalent (WT) booster group, following vaccination. However, this was only observed in individuals with prior infection. The relative fold change in serum binding IgA response was more skewed towards WT over variant (BA.1, BA.5 or EG.5.1) spike in previously infected bivalent-booster-vaccinees, as compared with previously infected monovalent-(WT)-booster-vaccinees. Conclusion: The findings suggest imprinting of antibody responses that is shaped by the first vaccination (WT spike). Previous infection also affects the boosting effect of follow-up vaccination. Studies are needed to understand how to induce a robust and long-lasting IgA immunity for protection against COVID-19 infection.
•Immune escape of SARS-CoV-2 variants spurred the development of bivalent vaccines.•We compared antibody response following monovalent or bivalent mRNA vaccination.•While IgG responses are similar, IgA responses are lower post bivalent booster.•IgA are particularly lower in bivalent-booster-vaccinees with prior infection.•IgA are skewed towards WT in bivalent-booster-vaccinees with prior infection. The emergence of new SARS-CoV-2 variants has led to the development of Omicron-targeting bivalent mRNA vaccines. It is crucial to understand how bivalent vaccines may improve antibody responses against new variants. A total of 107 participants, who had three COVID-19 WT mRNA vaccine doses, were recruited, and given either a monovalent (WT) or a bivalent mRNA vaccination (Pfizer/BioNTech Bivalent (WT and BA.4/BA.5) or Moderna Bivalent (WT and BA.1). Blood samples were taken before booster and at 28 days post-booster. We found significantly lower fold change in serum binding IgA responses against BA.1, BA.5 and EG.5.1 spike in the bivalent booster group, compared with the monovalent (WT) booster group, following vaccination. However, this was only observed in individuals with prior infection. The relative fold change in serum binding IgA response was more skewed towards WT over variant (BA.1, BA.5 or EG.5.1) spike in previously infected bivalent-booster-vaccinees, as compared with previously infected monovalent-(WT)-booster-vaccinees. The findings suggest imprinting of antibody responses that is shaped by the first vaccination (WT spike). Previous infection also affects the boosting effect of follow-up vaccination. Studies are needed to understand how to induce a robust and long-lasting IgA immunity for protection against COVID-19 infection.
The emergence of new SARS-CoV-2 variants has led to the development of Omicron-targeting bivalent mRNA vaccines. It is crucial to understand how bivalent vaccines may improve antibody responses against new variants.OBJECTIVESThe emergence of new SARS-CoV-2 variants has led to the development of Omicron-targeting bivalent mRNA vaccines. It is crucial to understand how bivalent vaccines may improve antibody responses against new variants.A total of 107 participants, who had three COVID-19 WT mRNA vaccine doses, were recruited, and given either a monovalent (WT) or a bivalent mRNA vaccination (Pfizer/BioNTech Bivalent (WT and BA.4/BA.5) or Moderna Bivalent (WT and BA.1). Blood samples were taken before booster and at 28 days post-booster.METHODSA total of 107 participants, who had three COVID-19 WT mRNA vaccine doses, were recruited, and given either a monovalent (WT) or a bivalent mRNA vaccination (Pfizer/BioNTech Bivalent (WT and BA.4/BA.5) or Moderna Bivalent (WT and BA.1). Blood samples were taken before booster and at 28 days post-booster.We found significantly lower fold change in serum binding IgA responses against BA.1, BA.5 and EG.5.1 spike in the bivalent booster group, compared with the monovalent (WT) booster group, following vaccination. However, this was only observed in individuals with prior infection. The relative fold change in serum binding IgA response was more skewed towards WT over variant (BA.1, BA.5 or EG.5.1) spike in previously infected bivalent-booster-vaccinees, as compared with previously infected monovalent-(WT)-booster-vaccinees.RESULTSWe found significantly lower fold change in serum binding IgA responses against BA.1, BA.5 and EG.5.1 spike in the bivalent booster group, compared with the monovalent (WT) booster group, following vaccination. However, this was only observed in individuals with prior infection. The relative fold change in serum binding IgA response was more skewed towards WT over variant (BA.1, BA.5 or EG.5.1) spike in previously infected bivalent-booster-vaccinees, as compared with previously infected monovalent-(WT)-booster-vaccinees.The findings suggest imprinting of antibody responses that is shaped by the first vaccination (WT spike). Previous infection also affects the boosting effect of follow-up vaccination. Studies are needed to understand how to induce a robust and long-lasting IgA immunity for protection against COVID-19 infection.CONCLUSIONThe findings suggest imprinting of antibody responses that is shaped by the first vaccination (WT spike). Previous infection also affects the boosting effect of follow-up vaccination. Studies are needed to understand how to induce a robust and long-lasting IgA immunity for protection against COVID-19 infection.
The emergence of new SARS-CoV-2 variants has led to the development of Omicron-targeting bivalent mRNA vaccines. It is crucial to understand how bivalent vaccines may improve antibody responses against new variants. A total of 107 participants, who had three COVID-19 WT mRNA vaccine doses, were recruited, and given either a monovalent (WT) or a bivalent mRNA vaccination (Pfizer/BioNTech Bivalent (WT and BA.4/BA.5) or Moderna Bivalent (WT and BA.1). Blood samples were taken before booster and at 28 days post-booster. We found significantly lower fold change in serum binding IgA responses against BA.1, BA.5 and EG.5.1 spike in the bivalent booster group, compared with the monovalent (WT) booster group, following vaccination. However, this was only observed in individuals with prior infection. The relative fold change in serum binding IgA response was more skewed towards WT over variant (BA.1, BA.5 or EG.5.1) spike in previously infected bivalent-booster-vaccinees, as compared with previously infected monovalent-(WT)-booster-vaccinees. The findings suggest imprinting of antibody responses that is shaped by the first vaccination (WT spike). Previous infection also affects the boosting effect of follow-up vaccination. Studies are needed to understand how to induce a robust and long-lasting IgA immunity for protection against COVID-19 infection.
ArticleNumber 107147
Author Loh, Chiew Yee
Lye, David C.
Fong, Siew‐Wai
Ng, Lisa F.P.
Hor, Pei Xiang
Ngoh, Eve Zi Xian
Salleh, Siti Nazihah Mohd
Young, Barnaby Edward
Goh, Yun Shan
Wang, Bei
Chia, Po Ying
Renia, Laurent
Wang, Cheng-I
Lee, I. Russel
Lee, Raphael Tze Chuen
Poh, Xuan Ying
Leo, Yee‐Sin
Tay, Matthew Zirui
Rao, Suma
Maurer-Stroh, Sebastian
AuthorAffiliation ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore
AuthorAffiliation_xml – name: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore
Author_xml – sequence: 1
  givenname: Yun Shan
  surname: Goh
  fullname: Goh, Yun Shan
  organization: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore
– sequence: 2
  givenname: Siew‐Wai
  surname: Fong
  fullname: Fong, Siew‐Wai
  organization: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore
– sequence: 3
  givenname: Pei Xiang
  surname: Hor
  fullname: Hor, Pei Xiang
  organization: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore
– sequence: 4
  givenname: Chiew Yee
  surname: Loh
  fullname: Loh, Chiew Yee
  organization: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore
– sequence: 5
  givenname: Matthew Zirui
  orcidid: 0000-0002-1763-913X
  surname: Tay
  fullname: Tay, Matthew Zirui
  organization: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore
– sequence: 6
  givenname: Bei
  orcidid: 0000-0002-3112-7341
  surname: Wang
  fullname: Wang, Bei
  organization: Singapore Immunology Network, ASTAR, Singapore, Singapore
– sequence: 7
  givenname: Siti Nazihah Mohd
  orcidid: 0000-0002-6110-7472
  surname: Salleh
  fullname: Salleh, Siti Nazihah Mohd
  organization: Singapore Immunology Network, ASTAR, Singapore, Singapore
– sequence: 8
  givenname: Eve Zi Xian
  orcidid: 0000-0001-5407-0280
  surname: Ngoh
  fullname: Ngoh, Eve Zi Xian
  organization: Singapore Immunology Network, ASTAR, Singapore, Singapore
– sequence: 9
  givenname: Raphael Tze Chuen
  surname: Lee
  fullname: Lee, Raphael Tze Chuen
  organization: Bioinformatics Institute, ASTAR, Singapore, Singapore
– sequence: 10
  givenname: Xuan Ying
  orcidid: 0000-0001-6077-0515
  surname: Poh
  fullname: Poh, Xuan Ying
  organization: National Centre for Infectious Diseases, Singapore, Singapore
– sequence: 11
  givenname: I. Russel
  surname: Lee
  fullname: Lee, I. Russel
  organization: National Centre for Infectious Diseases, Singapore, Singapore
– sequence: 12
  givenname: Suma
  surname: Rao
  fullname: Rao, Suma
  organization: National Centre for Infectious Diseases, Singapore, Singapore
– sequence: 13
  givenname: Po Ying
  orcidid: 0000-0002-8797-9527
  surname: Chia
  fullname: Chia, Po Ying
  organization: National Centre for Infectious Diseases, Singapore, Singapore
– sequence: 14
  givenname: Sebastian
  orcidid: 0000-0003-0813-9640
  surname: Maurer-Stroh
  fullname: Maurer-Stroh, Sebastian
  organization: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore
– sequence: 15
  givenname: Cheng-I
  surname: Wang
  fullname: Wang, Cheng-I
  organization: Singapore Immunology Network, ASTAR, Singapore, Singapore
– sequence: 16
  givenname: Yee‐Sin
  orcidid: 0000-0003-4978-5825
  surname: Leo
  fullname: Leo, Yee‐Sin
  organization: National Centre for Infectious Diseases, Singapore, Singapore
– sequence: 17
  givenname: David C.
  surname: Lye
  fullname: Lye, David C.
  organization: National Centre for Infectious Diseases, Singapore, Singapore
– sequence: 18
  givenname: Barnaby Edward
  surname: Young
  fullname: Young, Barnaby Edward
  organization: National Centre for Infectious Diseases, Singapore, Singapore
– sequence: 19
  givenname: Lisa F.P.
  surname: Ng
  fullname: Ng, Lisa F.P.
  organization: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore
– sequence: 20
  givenname: Laurent
  orcidid: 0000-0003-0349-1557
  surname: Renia
  fullname: Renia, Laurent
  email: renia_laurent@idlabs.a-star.edu.sg
  organization: ASTAR Infectious Diseases Labs (ASTAR ID Labs), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38945433$$D View this record in MEDLINE/PubMed
BookMark eNqNkUtvEzEUhUeoiD7gD7BAXpZFUj_mZcQmVDwiVSChIpbWtX0ncph4gj0JypJ_zg1TisQC2MzYV-d8ts85L07iELEongo-F1zUV-t5WAc_l1yWNGhE2TwozkTbtDNVCXFCa8nFTDdCnhbnOa8552Vdt4-KU9XqsiqVOiu-LzfbFOIY4ooNHVuuFixh3g4xY2Yhsm3CfRh2uT_QrkM3oqeFD_vgd9BnEjukDblt2EOPcWSbj-8XbA_OhUiMy8-3DKJnrxbz8oo-FRsS-z0Tzx8XDzsi4ZO7_0Xx6c3r2-t3s5sPb5fXi5uZK-t2nHlQTSc7rLrOcuAeOs21bmruEbD1XEvgqDVyKyWIunHaSm21wsZaqG2jLorlxPUDrA09egPpYAYI5udgSCsDaQyuRyM4lFxWJVKqZdURUmtKXGgtWxDWEktNrF3cwuEb9P09UHBzLMeszbEccyzHTOWQ63JybdPwdYd5NJuQHfY9RKSIjaLThFJVzUn67E66sxv09_RfxZFATgKXhpwTdv93gZeTCSnnfcBksgsYHfpAPY4URPi7_cUfdteHGBz0X_DwL_MPz-TRvg
Cites_doi 10.1038/s41598-023-46800-x
10.1126/science.abq1841
10.1371/journal.pone.0249499
10.3389/fimmu.2023.1100263
10.1056/NEJMc2213907
10.1038/s41385-022-00511-0
10.1038/s41586-021-04389-z
10.1038/s41467-024-47429-8
ContentType Journal Article
Copyright 2024 The Author(s)
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Copyright_xml – notice: 2024 The Author(s)
– notice: Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
CorporateAuthor PRIBIVAC Cohort Study Group
CorporateAuthor_xml – name: PRIBIVAC Cohort Study Group
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ADTOC
UNPAY
DOA
DOI 10.1016/j.ijid.2024.107147
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1878-3511
ExternalDocumentID oai_doaj_org_article_10a40254e10745f0b29910119928a1bb
10.1016/j.ijid.2024.107147
38945433
10_1016_j_ijid_2024_107147
S1201971224002182
Genre Journal Article
GroupedDBID ---
--K
.1-
.FO
.~1
0R~
1B1
1P~
1~.
1~5
29J
3O-
4.4
457
4G.
53G
5GY
5VS
7-5
71M
7X7
88E
8C1
8FI
8FJ
8FQ
8R4
8R5
AAEDW
AAFWJ
AAIKJ
AALRI
AAQFI
AAQXK
AARKO
AAXUO
AAYWO
ABBQC
ABFRF
ABMAC
ABUWG
ABWVN
ACGFO
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADVLN
AEFWE
AEKER
AENEX
AEUPX
AEVXI
AEXQZ
AFJKZ
AFKRA
AFPKN
AFPUW
AFRHN
AFTJW
AGEKW
AGHFR
AGQPQ
AGYEJ
AHMBA
AIGII
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APXCP
ASPBG
AVWKF
AZFZN
BAWUL
BCNDV
BENPR
BPHCQ
BR6
BVXVI
CCPQU
CS3
DIK
DU5
DWQXO
E3Z
EBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FNPLU
FYUFA
G-Q
GBLVA
GROUPED_DOAJ
GX1
HMCUK
HVGLF
HZ~
IHE
IXB
J1W
KQ8
M1P
M3C
M3G
M41
MO0
N9A
O-L
O9-
OD-
OK1
OO.
OZT
P-8
P-9
P2P
PC.
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
Q2X
Q38
QTD
R2-
ROL
RPZ
RWL
RXW
SDF
SDG
SEL
SES
SEW
SSZ
TAE
UKHRP
UNMZH
Z5R
0SF
3V.
6I.
AACTN
AAFTH
ABVKL
AFCTW
ALIPV
NCXOZ
RIG
AAYXX
CITATION
~HD
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ADTOC
UNPAY
ID FETCH-LOGICAL-c468t-da37f2fe5ffb0a0daf9099760deae8d092a0e99e0b22a167c9b29b93e7bba6b73
IEDL.DBID DOA
ISSN 1201-9712
1878-3511
IngestDate Wed Aug 27 01:31:16 EDT 2025
Wed Aug 20 00:16:01 EDT 2025
Mon Sep 29 03:52:56 EDT 2025
Mon Jul 21 05:55:51 EDT 2025
Wed Oct 01 05:07:40 EDT 2025
Sat Aug 10 15:31:11 EDT 2024
Tue Aug 26 18:38:49 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords Bivalent
Variant
EG.5.1
SARS-CoV-2
IgA
mRNA vaccine
Language English
License This is an open access article under the CC BY-NC-ND license.
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c468t-da37f2fe5ffb0a0daf9099760deae8d092a0e99e0b22a167c9b29b93e7bba6b73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-5407-0280
0000-0003-0349-1557
0000-0001-6077-0515
0000-0002-1763-913X
0000-0003-0813-9640
0000-0003-4978-5825
0000-0002-8797-9527
0000-0002-3112-7341
0000-0002-6110-7472
OpenAccessLink https://doaj.org/article/10a40254e10745f0b29910119928a1bb
PMID 38945433
PQID 3074133560
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_10a40254e10745f0b29910119928a1bb
unpaywall_primary_10_1016_j_ijid_2024_107147
proquest_miscellaneous_3074133560
pubmed_primary_38945433
crossref_primary_10_1016_j_ijid_2024_107147
elsevier_sciencedirect_doi_10_1016_j_ijid_2024_107147
elsevier_clinicalkey_doi_10_1016_j_ijid_2024_107147
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate September 2024
2024-09-00
2024-Sep
20240901
2024-09-01
PublicationDateYYYYMMDD 2024-09-01
PublicationDate_xml – month: 09
  year: 2024
  text: September 2024
PublicationDecade 2020
PublicationPlace Canada
PublicationPlace_xml – name: Canada
PublicationTitle International journal of infectious diseases
PublicationTitleAlternate Int J Infect Dis
PublicationYear 2024
Publisher Elsevier Ltd
Elsevier
Publisher_xml – name: Elsevier Ltd
– name: Elsevier
References Urschel, Bronder, Klemis, Marx, Hielscher, Abu-Omar (bib0006) 2024; 15
Cao, Jian, Wang, Yu, Song, Yisimayi (bib0004) 2023; 614
Reynolds, Pade, Gibbons, Otter, Lin, Munoz Sandoval (bib0005) 2022; 377
Goh, Chavatte, Lim Jieling, Lee, Hor, Amrun (bib0002) 2021; 2
Liew, Kua, Lee, Wong (bib0008) 2023; 14
Goh, Fong, Tay, Rouers, Chang, Chavatte (bib0010) 2023; 13
Sheikh-Mohamed, Isho, Chao, Zuo, Cohen, Lustig (bib0009) 2022; 15
Wisnewski, Campillo Luna, Redlich (bib0007) 2021; 16
Planas, Saunders, Maes, Guivel-Benhassine, Planchais, Buchrieser (bib0001) 2022; 602
Wang, Bowen, Valdez, Gherasim, Gordon, Liu (bib0003) 2023; 388
Goh (10.1016/j.ijid.2024.107147_bib0010) 2023; 13
Goh (10.1016/j.ijid.2024.107147_bib0002) 2021; 2
Sheikh-Mohamed (10.1016/j.ijid.2024.107147_bib0009) 2022; 15
Urschel (10.1016/j.ijid.2024.107147_bib0006) 2024; 15
Wisnewski (10.1016/j.ijid.2024.107147_bib0007) 2021; 16
Cao (10.1016/j.ijid.2024.107147_bib0004) 2023; 614
Planas (10.1016/j.ijid.2024.107147_bib0001) 2022; 602
Wang (10.1016/j.ijid.2024.107147_bib0003) 2023; 388
Reynolds (10.1016/j.ijid.2024.107147_bib0005) 2022; 377
Liew (10.1016/j.ijid.2024.107147_bib0008) 2023; 14
References_xml – volume: 13
  start-page: 19331
  year: 2023
  ident: bib0010
  article-title: Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta wave
  publication-title: Sci Rep
– volume: 2
  year: 2021
  ident: bib0002
  article-title: Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19
  publication-title: Cell Rep Med
– volume: 15
  start-page: 3077
  year: 2024
  ident: bib0006
  article-title: SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals
  publication-title: Nat Commun
– volume: 602
  start-page: 671
  year: 2022
  end-page: 675
  ident: bib0001
  article-title: Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
  publication-title: Nature
– volume: 377
  start-page: eabq1841
  year: 2022
  ident: bib0005
  article-title: Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
  publication-title: Science
– volume: 388
  start-page: 567
  year: 2023
  end-page: 569
  ident: bib0003
  article-title: Antibody response to Omicron BA.4-BA.5 bivalent booster
  publication-title: N Engl J Med
– volume: 14
  year: 2023
  ident: bib0008
  article-title: SARS-CoV-2 neutralizing antibody bebtelovimab—a systematic scoping review and meta-analysis
  publication-title: Front Immunol
– volume: 15
  start-page: 799
  year: 2022
  end-page: 808
  ident: bib0009
  article-title: Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection
  publication-title: Mucosal Immunol
– volume: 16
  year: 2021
  ident: bib0007
  article-title: Human IgG and IgA responses to COVID-19 mRNA vaccines
  publication-title: PLoS One
– volume: 614
  start-page: 521
  year: 2023
  end-page: 529
  ident: bib0004
  article-title: Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution
  publication-title: Nature
– volume: 13
  start-page: 19331
  year: 2023
  ident: 10.1016/j.ijid.2024.107147_bib0010
  article-title: Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta wave
  publication-title: Sci Rep
  doi: 10.1038/s41598-023-46800-x
– volume: 614
  start-page: 521
  issue: 7948
  year: 2023
  ident: 10.1016/j.ijid.2024.107147_bib0004
  article-title: Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution
  publication-title: Nature
– volume: 2
  issue: 2
  year: 2021
  ident: 10.1016/j.ijid.2024.107147_bib0002
  article-title: Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19
  publication-title: Cell Rep Med
– volume: 377
  start-page: eabq1841
  issue: 6603
  year: 2022
  ident: 10.1016/j.ijid.2024.107147_bib0005
  article-title: Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
  publication-title: Science
  doi: 10.1126/science.abq1841
– volume: 16
  issue: 6
  year: 2021
  ident: 10.1016/j.ijid.2024.107147_bib0007
  article-title: Human IgG and IgA responses to COVID-19 mRNA vaccines
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0249499
– volume: 14
  year: 2023
  ident: 10.1016/j.ijid.2024.107147_bib0008
  article-title: SARS-CoV-2 neutralizing antibody bebtelovimab—a systematic scoping review and meta-analysis
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2023.1100263
– volume: 388
  start-page: 567
  issue: 6
  year: 2023
  ident: 10.1016/j.ijid.2024.107147_bib0003
  article-title: Antibody response to Omicron BA.4-BA.5 bivalent booster
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2213907
– volume: 15
  start-page: 799
  issue: 5
  year: 2022
  ident: 10.1016/j.ijid.2024.107147_bib0009
  article-title: Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection
  publication-title: Mucosal Immunol
  doi: 10.1038/s41385-022-00511-0
– volume: 602
  start-page: 671
  issue: 7898
  year: 2022
  ident: 10.1016/j.ijid.2024.107147_bib0001
  article-title: Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
  publication-title: Nature
  doi: 10.1038/s41586-021-04389-z
– volume: 15
  start-page: 3077
  issue: 1
  year: 2024
  ident: 10.1016/j.ijid.2024.107147_bib0006
  article-title: SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals
  publication-title: Nat Commun
  doi: 10.1038/s41467-024-47429-8
SSID ssj0004668
Score 2.394046
Snippet •Immune escape of SARS-CoV-2 variants spurred the development of bivalent vaccines.•We compared antibody response following monovalent or bivalent mRNA...
The emergence of new SARS-CoV-2 variants has led to the development of Omicron-targeting bivalent mRNA vaccines. It is crucial to understand how bivalent...
Objectives: The emergence of new SARS-CoV-2 variants has led to the development of Omicron-targeting bivalent mRNA vaccines. It is crucial to understand how...
SourceID doaj
unpaywall
proquest
pubmed
crossref
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 107147
SubjectTerms Adult
Aged
Antibodies, Viral - blood
Bivalent
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 - virology
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - immunology
EG.5.1
Female
Humans
IgA
Immunization, Secondary
Immunoglobulin A - blood
Male
Middle Aged
mRNA vaccine
mRNA Vaccines
SARS-CoV-2
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
Spike Glycoprotein, Coronavirus - genetics
Spike Glycoprotein, Coronavirus - immunology
Vaccination
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - immunology
Variant
Young Adult
SummonAdditionalLinks – databaseName: ScienceDirect
  dbid: IXB
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VPfBQhaC8wktG4gCCsEnsPHzcragKUnuAVuwtshO7crUkq30U9cg_ZyZOlq2QAHGJFGuSOJnJzNj-vjHAK1kLDAK2CmVtMxygpEWoqpxGKYYXiTRS18RGPj7Jjs7Ep2k63YGDgQtDsMre93uf3nnrvmXUf83R3LnRlxhjl8zjDgVJdcjRD3ORdyS-6WSLG-npcCgcknRPnPEYL3fhqFpoIrAhj2mLla3g1NXwvxajfs9Bb8PNdTNXV9_VbLYVlw7vwp0-oWRj3-d7sGOafbhx3C-Z78Oen5hjnm90H37QNILr9odgrWUfz8ds4XGyZslcw-aE-23Xy9kV80AtUzO3YW0tUbgyjmYhmHZopRiz2LfPJ2N2qSp64JK9_nrKVFOzyfi9GOEhZe2C_WqL3zyAs8MPpwdHYb8PQ1iJrFiFteK5TaxJrdWRimplJfFts6g2yhR1JBMVGSlNpJNExVleSZ1ILbnJtVaZzvlD2G3axjwGZmSGt-JGChwJKR4VWsdFpbXUuVQ2iQN4OyignPtyG-WAQ7soSV0lqav06gpgQjraSFKp7K6hXZyXva2gqBJE-TcEPU0tdhJTYqp0J5NCxVoHwAcNlwMbFf0n3sj98dHp5qpr9vrX614ORlTij0yrM6oxqNWSU3LHOWagATzy1rV5McwqRSo4D-Ddxtz-4fs8-c9OPoVbdOahdM9gd7VYm-eYe630i-7n-gmQqib-
  priority: 102
  providerName: Elsevier
Title Imprinting of IgA responses in previously infected individuals receiving bivalent mRNA vaccines (WT and BA.4/BA.5 or WT and BA.1)
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1201971224002182
https://dx.doi.org/10.1016/j.ijid.2024.107147
https://www.ncbi.nlm.nih.gov/pubmed/38945433
https://www.proquest.com/docview/3074133560
https://doi.org/10.1016/j.ijid.2024.107147
https://doaj.org/article/10a40254e10745f0b29910119928a1bb
UnpaywallVersion publishedVersion
Volume 146
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1878-3511
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0004668
  issn: 1201-9712
  databaseCode: KQ8
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1878-3511
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0004668
  issn: 1201-9712
  databaseCode: KQ8
  dateStart: 19960701
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1878-3511
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0004668
  issn: 1201-9712
  databaseCode: DOA
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVESC
  databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier)
  customDbUrl:
  eissn: 1878-3511
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0004668
  issn: 1201-9712
  databaseCode: GBLVA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection
  customDbUrl:
  eissn: 1878-3511
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0004668
  issn: 1201-9712
  databaseCode: .~1
  dateStart: 19960701
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: ScienceDirect
  customDbUrl:
  eissn: 1878-3511
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0004668
  issn: 1201-9712
  databaseCode: IXB
  dateStart: 19960701
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1878-3511
  dateEnd: 20241001
  omitProxy: true
  ssIdentifier: ssj0004668
  issn: 1201-9712
  databaseCode: DIK
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1878-3511
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0004668
  issn: 1201-9712
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 1878-3511
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0004668
  issn: 1201-9712
  databaseCode: AKRWK
  dateStart: 19960701
  isFulltext: true
  providerName: Library Specific Holdings
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB5BDzyEEJRXeFRG4gCClCR2Hj7uIqoWqT2gVuzNsmMbpVqyq32AekHinzOzTsIiJMqBiw-WH4m_sWdszzcGeCGtQCXg61haX-AGJa9iXZe0S3G8yqSTxhIb-fikODwTHyb5ZOupL_IJC-GBw8DhrNaCGNuOPAdznxhcP1MKVCazSqfG0OqLaqzfTA2MyECCQ_UWyzLNOrpM8OxqzhuKEZoJzChTelhlSyVtIvf_ppn-tDxvwvV1O9cX3_R0uqWNDu7A7c6MZKPw-Xfhimt34dpxd1G-C7fCcRwLLKN78IMOD5rNqxBs5tnR5xFbBO9Yt2RNy-bk7TtbL6cXLLhnOcuagau1xMK1a-jsgZkGZRM1Ffvy8WTEvuqaOlyyl59OmW4tG4_2xVtMcjZbsF956av7cHbw_vTdYdy9vhDXoqhWsdW89Jl3ufcm0YnVXhLLtkis066yicx04qR0iEim06KsJUJjJHelMbowJX8AO-2sdY-AOVlgU9xJgfsfzZPKmLSqjZGmlNpnaQSvewDUPATZUL332bkiuBTBpQJcEYwJo6EkBcjeZKDYqE5s1GViEwHvEVY9BxVXTWyo-WvX-VCrs1CC5XFpvee9ECmcvnQno1uHqCpOJh3naHdG8DBI1_BjaEuKXHAewZtB3P5hfB7_j_F5AjeoyeBN9xR2Vou1e4bm18rswdX97-neZr5hejQZ_wRsCSbg
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlEQQlBe4WkkDiBIN4nz8nFbUW2huwfYit4sO3GqVEuy2geoFyT-OTNxErZCAsQlB2fiOJmxZ2x_3xjgpchDdAJF5oq8iHGCEqWuyhKapRieBsIInRMbeTyJRyfh-9PodAsOOi4MwSrbsd-O6c1o3ZYM2r85mJfl4JOPvkskfoOCpDzkV-BqSBaFRr333d8gR1o-HEq7JN4yZyzIqzwvKV1oEGJB4tMZKxveqUnif8lJ_R6E3oCddTVXF9_UbLbhmA5vw602omRD2-g7sGWqXbg2bvfMd-GmXZljlnB0F37QOkLZHBDB6oIdnQ3ZwgJlzZKVFZsT8LdeL2cXzCK1TM7Knra1ROHMlLQMwXSJZopOi335OBmyryqjFy7Zq89Tpqqc7Q_3wgFeIlYv2K8y__U9ODl8Nz0Yue1BDG4WxunKzRVPiqAwUVFoT3m5KgQRbmMvN8qkuScC5RkhjKeDQPlxkgkdCC24SbRWsU74fdiu6so8BGZEjFVxI0KcCinupVr7aaa10IlQReA78KZTgJzbfBuyA6KdS1KXJHVJqy4H9klHvSTlym4K6sWZbI0FRVVInH9D2NOowEZiTEyp7kSQKl9rB3inYdnRUXEAxYrKP7466p-6ZLB_fe5FZ0QSezJtz6jKoFYlp-iOcwxBHXhgrav_MAwrwyjk3IG3vbn9w_959J-NfA47o-n4WB4fTT48hut0x-LqnsD2arE2TzEQW-lnTUf7CU4nKhI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Imprinting+of+IgA+responses+in+previously+infected+individuals+receiving+bivalent+mRNA+vaccines+%28WT+and+BA.4%2FBA.5+or+WT+and+BA.1%29&rft.jtitle=International+journal+of+infectious+diseases&rft.au=Goh%2C+Yun+Shan&rft.au=Fong%2C+Siew-Wai&rft.au=Hor%2C+Pei+Xiang&rft.au=Loh%2C+Chiew+Yee&rft.date=2024-09-01&rft.eissn=1878-3511&rft.volume=146&rft.spage=107147&rft_id=info:doi/10.1016%2Fj.ijid.2024.107147&rft_id=info%3Apmid%2F38945433&rft.externalDocID=38945433
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1201-9712&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1201-9712&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1201-9712&client=summon